You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

161 Results
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant
Aug 2019
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Adjuvant, Palliative
May 2019
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
May 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Palliative
May 2019
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Intent: Adjuvant
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    tamoxifen
Feb 2025
Regimen
Intent: Adjuvant, Curative
Funding:
Exceptional Access Program
    daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Exceptional Access Program
    trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Jun 2021
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Apr 2023

Pages